Myomo Q4 revenue flat at $4.0M; net loss improves to $0.29/share

MYOMO, INC.

Q4 product revenue $4.0M, flat YoY and up 2% sequentially; 101 units (down 6% YoY).
Net loss attributable to common stockholders $2.2M ($0.29/share) vs $3.4M ($0.52) prior year.
Gross margin 65.0% (down from 77.4% YoY) due to inflationary costs; operating expenses down 17%.
Patient pipeline added 387 new candidates (+75% YoY); cost per pipeline add down 45% to $2,665.
Jan 2023 workforce cut 12% to save ~$2.0M; guided Q1 product revenue +15-20% YoY, FY +20-30%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.